Back to Search

A First -in Human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Repeated Intravenous Infusions in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

  • Protocol Number: 202009216
  • Principal Investigator: Morgensztern, Daniel
  • Cancer Types: Lung

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions